Books on the topic 'Metalloproteinases Inhibitors Therapeutic use'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the top 50 books for your research on the topic 'Metalloproteinases Inhibitors Therapeutic use.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Browse books on a wide variety of disciplines and organise your bibliography correctly.
Rotheim, Philip. New developments in therapeutic enzyme inhibitors and receptor blockers. Norwalk, CT: Business Communications Co., 1996.
Goudot-Perrot, Andrée. Metabolic inhibitors: Antibiotics - antimitotics - psychotropics. Stuttgart: Schwer Verlag, 1992.
Co, Business Communications. New developments in therapeutic enzyme inhibitors and blockers. Norealk, CT: Business Communications Co., 2002.
George, Weinbaum, Giles Ralph E, Krell Robert D, New York Academy of Sciences., and American Thoracic Society, eds. Pulmonary emphysema: The rationale for therapeutic intervention. New York, N.Y: New York Academy of Sciences, 1991.
PhD, Henderson Brian, and Bodmer Mark W, eds. Therapeutic modulation of cytokines. Boca Raton, Fla: CRC Press, 1996.
K, Ghosh Arun. Aspartic acid proteases as therapeutic targets. Weinheim: Wiley-VCH, 2010.
K, Ghosh Arun. Aspartic acid proteases as therapeutic targets. Weinheim: Wiley-VCH, 2010.
Philippe, Taupin, ed. The cystatin superfamily of proteinase inhibitors. New York: Nova Science Publishers, 2007.
Osiadacz, Jarosław. Inhibitory topoizomeraz DNA i ich zastosowanie w chemioterapii. Wrocław: Oficyna Wydawnicza Politechniki Wrocławskiej, 1999.
Li, William W. The antiangiogenic therapy self help book for cancer patients. Cambridge, Mass: Angiogenesis Foundation, 2003.
International FOIPAN Symposium. (1988 Shizuoka, Japan). Therapeutic basis of synthetic protease inhibitor: Proceedings of the International FOIPAN Symposium held as a Satellite of the 7th International Symposium on Gastrointestinal Hormones, November 4, 1988, Shizuoka, Japan. Edited by Kanno Tomio 1933-, Miyoshi A, Biomedical Research Foundation (Japan), and International Symposium on Gastrointestinal Hormones. (7th : 1988 : Shizuoka, Japan). Tokyo: Biomedical Research Foundation, 1989.
Mantovani, Alberto. Pharmacology of cytokines. Oxford: Oxford University Press, 2000.
N, DeBrue Anne, ed. Angiotensin converting enzyme inhibitors. New York: Nova Biomedical Books, 2009.
Lane, I. William. Comprehensive research papers on the therapeutic use of shark cartilage. Kerrville, TX: Information Services, 1992.
Chiba, Tsutomu, P. Malfertheiner, and Hiroshi Satoh. Proton pump inhibitors: A balanced view. Basel: Karger, 2013.
Strube, Gillian. ACE inhibitors in hypertension: A guide for general practitioners. Dordrecht: Kluwer Academic Publishers, 1992.
Shiau, Judy Y. The efficacy of proton pump inhibitors in adults with functional dyspepsia. Ottawa: Canadian Coordinating Office for Health Technology Assessment, 2002.
H, Opie Lionel. Angiotensin-converting enzyme inhibitors: Scientific basis for clinical use. New York: Wiley-Liss, 1992.
Ezio, Giacobini, and Becker Robert E, eds. Current research in Alzheimer therapy: Cholinesterase inhibitors. New York: Taylor & Francis, 1988.
Chang, Henry E. HIV protease inhibitor report. 2nd ed. Brooklyn, NY (72 Orange St., #3C, Brooklyn 11201): National AIDS Treatment Advocacy Project, 1996.
National Institute for Clinical Excellence (Great Britain). Guidance on the use of donepezil, rivastigmine and galantamine for the treatment of Alzheimer's disease. London: National Institute for Clinical Excellence, 2001.
Donnelly, Raymond P. Cytokine therapies: Novel approaches for clinical indications. Boston, Mass: Blackwell Pub. on behalf of the New York Academy of Sciences, 2009.
Krul, Kenneth G. Transcription inhibitors: The next generation of therapeutics. Waltham, Mass: Decision Resources, Inc., 1996.
H, Opie Lionel. Angiotensin-converting enzyme inhibitors: Scientific basis for clinical use. New York: Wiley-Liss, 1992.
K, Ferguson Roger, and Vlasses Peter, eds. Angiotensin-converting enzyme inhibitors. Mount Kisco, N.Y: Futura Pub. Co., 1987.
1943-, Greenwald Robert A., Golub Lorne M, and New York Academy of Sciences., eds. Inhibition of matrix metalloproteinases: Therapeutic potential. New York, N.Y: New York Academy of Sciences, 1994.
Clendeninn, Neil J., and Krzysztof Appelt. Matrix Metalloproteinase Inhibitors in Cancer Therapy. Humana Press, 2000.
(Editor), Robert A. Greenwald, New York Academy of Sciences (Corporate Author), and Lorne M. Golub (Editor), eds. Inhibition of Matrix Metalloproteinases: Therapeutic Potential (Annals of the New York Academy of Sciences). New York Academy of Sciences, 1994.
(Editor), Robert A. Greenwald, Stanley Zucker (Editor), and Lorne M. Golub (Editor), eds. Inhibition of Matrix Metalloproteinases: Therapeutic Applications (Annals of the New York Academy of Sciences). New York Academy of Sciences, 1999.
Kevin M.K. Bottomley (Editor), David Bradshaw (Editor), and John S. Nixon (Editor), eds. Metalloproteinases as Targets for Anti-Inflammatory Drugs (Progress in Inflammation Research). Birkhäuser Basel, 1999.
(Editor), Robert A. Greenwald, New York Academy of Sciences (Corporate Author), and Lorne M. Golub (Editor), eds. Inhibition of Matrix Metalloproteinases: Therapeutic Potential (Annals of the New York Academy of Sciences, Vol 732). New York Academy of Sciences, 1994.
(Editor), Neil J. Clendeninn, and Krzysztof Appelt (Editor), eds. Matrix Metalloproteinase Inhibitors in Cancer Therapy (Cancer Drug Discovery and Development). Humana Press, 2001.
Therapeutic Kinase Inhibitors. Springer, 2012.
Page, Clive, Christian Schudt, Gordon Dent, and Klaus F. Rabe. Phosphodiesterase Inhibitors. Elsevier Science & Technology Books, 1996.
1957-, D'Orléans-Juste P., and Plante G. E, eds. ACE inhibitors. Basel: Birkhäuser Verlag, 2001.
Inhibitors of Cyclin-dependent Kinases as Anti-tumor Agents (Crc Enzyme Inhibitors). CRC, 2006.
Xu, Jun-Ping. Cancer Inhibitors from Chinese Natural Medicines. Taylor & Francis Group, 2016.
Xu, Jun-Ping. Cancer Inhibitors from Chinese Natural Medicines. Taylor & Francis Group, 2016.
Xu, Jun-Ping. Cancer Inhibitors from Chinese Natural Medicines. Taylor & Francis Group, 2016.
Xu, Jun-Ping. Cancer Inhibitors from Chinese Natural Medicines. Taylor & Francis Group, 2016.
Xu, Jun-Ping. Cancer Inhibitors from Chinese Natural Medicines. Taylor & Francis Group, 2021.
Xu, Jun-Ping. Cancer Inhibitors from Chinese Natural Medicines. Taylor & Francis Group, 2016.
Weinbaum, George, Ralph E. Giles, and Robert D. Krell. Pulmonary emphysema : The rationale for therapeutic intervention. New York Academy of Sciences, 1991.
Machajewski, Timothy D., Zhenhai Gao, Brian Blagg, Tim Haystead, and Len Neckers. Inhibitors of Molecular Chaperones As Therapeutic Agents. Royal Society of Chemistry, The, 2013.
Picard, Didier, Timothy D. Machajewski, Zhenhai Gao, David P. Rotella, and Chrisostomos Prodromou. Inhibitors of Molecular Chaperones As Therapeutic Agents. Royal Society of Chemistry, The, 2013.
Aromatase inhibitors. Basel: Birkhäuser, 2006.
Brodie, Angela, J. Michael Dixon, Robert Paridaens, Miller William R, and B. J. A. Furr. Aromatase Inhibitors. Springer London, Limited, 2006.
Brodie, Angela, Aman Buzdar, Per Eystein Lonning, J. Michael Dixon, and B. J. A. Furr. Aromatase Inhibitors. Birkhauser Verlag, 2008.
Mousa, Shaker A. Angiogenesis Inhibitors and Stimulators: Potential Therapeutic Implications. Taylor & Francis Group, 2000.
Zhang, Jie. PARP as a Therapeutic Target (Handbooks in Pharmacology and Toxicology). CRC, 2002.